Recent progress in identification methods for human tumor antigens recognized by T cells

Emiko Hayashi, Yuriko Matsuzaki, Yutaka Kawakami

Research output: Contribution to journalArticle

Abstract

Recent identification of human tumor antigens recognized by T cells made it possible to analyze anti-tumor immune responses quantitatively and qualitatively in human and to develop immunotherapy in a more scientific way. The identification methods have been being improved during the past 10 years. When tumor reactive T-cells are available, DNA expression cloning or direct peptide sequencing from HPLC fractions extracted from MHC class I/peptide complex can be performed. However, it is difficult to establish tumor reactive T cells in many tumors. In those cases, we can apply the reverse immunology approach, in which tumor antigen candidates are first identified by various genetic or immunological methods, including cDNA subtraction between cancers and various tissues with cDNA profiles obtained through systematic gene analysis such as DNA chip/microarrays, SAGE, or public gene databases, or cDNA expression cloning with patients' sera (SEREX). Then antigenicity of the identified candidates is confirmed by demonstration of T cell induction against candidates through in vitro T cell induction or immunization of HLA transgenic mice. We have made various modifications on these techniques. Identification of human tumor antigens in various cancers will lead to development of more effective immunotherapy in the future.

Original languageEnglish
Pages (from-to)497-502
Number of pages6
JournalBiotherapy
Volume18
Issue number6
Publication statusPublished - 2004 Nov

Fingerprint

Forensic Anthropology
Neoplasm Antigens
T-Lymphocytes
Neoplasms
Complementary DNA
Oligonucleotide Array Sequence Analysis
Immunotherapy
Organism Cloning
Peptides
Allergy and Immunology
Transgenic Mice
Genes
Immunization
High Pressure Liquid Chromatography
Databases
DNA
Serum

Keywords

  • cDNA expression cloning
  • HLA transgenic mice
  • Immunotherapy
  • Systematic gene analysis
  • Tumor antigens

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Recent progress in identification methods for human tumor antigens recognized by T cells. / Hayashi, Emiko; Matsuzaki, Yuriko; Kawakami, Yutaka.

In: Biotherapy, Vol. 18, No. 6, 11.2004, p. 497-502.

Research output: Contribution to journalArticle

Hayashi, Emiko ; Matsuzaki, Yuriko ; Kawakami, Yutaka. / Recent progress in identification methods for human tumor antigens recognized by T cells. In: Biotherapy. 2004 ; Vol. 18, No. 6. pp. 497-502.
@article{0d6aaebb7edf47a586c130d1ef656a5e,
title = "Recent progress in identification methods for human tumor antigens recognized by T cells",
abstract = "Recent identification of human tumor antigens recognized by T cells made it possible to analyze anti-tumor immune responses quantitatively and qualitatively in human and to develop immunotherapy in a more scientific way. The identification methods have been being improved during the past 10 years. When tumor reactive T-cells are available, DNA expression cloning or direct peptide sequencing from HPLC fractions extracted from MHC class I/peptide complex can be performed. However, it is difficult to establish tumor reactive T cells in many tumors. In those cases, we can apply the reverse immunology approach, in which tumor antigen candidates are first identified by various genetic or immunological methods, including cDNA subtraction between cancers and various tissues with cDNA profiles obtained through systematic gene analysis such as DNA chip/microarrays, SAGE, or public gene databases, or cDNA expression cloning with patients' sera (SEREX). Then antigenicity of the identified candidates is confirmed by demonstration of T cell induction against candidates through in vitro T cell induction or immunization of HLA transgenic mice. We have made various modifications on these techniques. Identification of human tumor antigens in various cancers will lead to development of more effective immunotherapy in the future.",
keywords = "cDNA expression cloning, HLA transgenic mice, Immunotherapy, Systematic gene analysis, Tumor antigens",
author = "Emiko Hayashi and Yuriko Matsuzaki and Yutaka Kawakami",
year = "2004",
month = "11",
language = "English",
volume = "18",
pages = "497--502",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "6",

}

TY - JOUR

T1 - Recent progress in identification methods for human tumor antigens recognized by T cells

AU - Hayashi, Emiko

AU - Matsuzaki, Yuriko

AU - Kawakami, Yutaka

PY - 2004/11

Y1 - 2004/11

N2 - Recent identification of human tumor antigens recognized by T cells made it possible to analyze anti-tumor immune responses quantitatively and qualitatively in human and to develop immunotherapy in a more scientific way. The identification methods have been being improved during the past 10 years. When tumor reactive T-cells are available, DNA expression cloning or direct peptide sequencing from HPLC fractions extracted from MHC class I/peptide complex can be performed. However, it is difficult to establish tumor reactive T cells in many tumors. In those cases, we can apply the reverse immunology approach, in which tumor antigen candidates are first identified by various genetic or immunological methods, including cDNA subtraction between cancers and various tissues with cDNA profiles obtained through systematic gene analysis such as DNA chip/microarrays, SAGE, or public gene databases, or cDNA expression cloning with patients' sera (SEREX). Then antigenicity of the identified candidates is confirmed by demonstration of T cell induction against candidates through in vitro T cell induction or immunization of HLA transgenic mice. We have made various modifications on these techniques. Identification of human tumor antigens in various cancers will lead to development of more effective immunotherapy in the future.

AB - Recent identification of human tumor antigens recognized by T cells made it possible to analyze anti-tumor immune responses quantitatively and qualitatively in human and to develop immunotherapy in a more scientific way. The identification methods have been being improved during the past 10 years. When tumor reactive T-cells are available, DNA expression cloning or direct peptide sequencing from HPLC fractions extracted from MHC class I/peptide complex can be performed. However, it is difficult to establish tumor reactive T cells in many tumors. In those cases, we can apply the reverse immunology approach, in which tumor antigen candidates are first identified by various genetic or immunological methods, including cDNA subtraction between cancers and various tissues with cDNA profiles obtained through systematic gene analysis such as DNA chip/microarrays, SAGE, or public gene databases, or cDNA expression cloning with patients' sera (SEREX). Then antigenicity of the identified candidates is confirmed by demonstration of T cell induction against candidates through in vitro T cell induction or immunization of HLA transgenic mice. We have made various modifications on these techniques. Identification of human tumor antigens in various cancers will lead to development of more effective immunotherapy in the future.

KW - cDNA expression cloning

KW - HLA transgenic mice

KW - Immunotherapy

KW - Systematic gene analysis

KW - Tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=10844272304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10844272304&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:10844272304

VL - 18

SP - 497

EP - 502

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 6

ER -